Indeed, SIRT5 inhibition by MC3482 might offer a novel pharmacological strategy to be considered in metabolic and cardiovascular rehabilitation programs to improve quality of life of obese subjects with T2D and metabolic syndrome. This evidence concerns the gene SIRT5 and type 2 diabetes mellitus.